Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Issues Earnings Results

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) issued its quarterly earnings data on Friday. The company reported ($0.02) EPS for the quarter, FiscalAI reports.

Oaktree Acquisition Corp. III Life Sciences Price Performance

NASDAQ:OACC traded up $0.01 during trading hours on Friday, reaching $10.71. 825 shares of the company traded hands, compared to its average volume of 4,801. The firm’s 50-day moving average is $10.74 and its 200-day moving average is $10.70. Oaktree Acquisition Corp. III Life Sciences has a 1-year low of $10.50 and a 1-year high of $10.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

A number of institutional investors have recently made changes to their positions in the stock. Periscope Capital Inc. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the third quarter valued at $3,488,000. DLD Asset Management LP increased its position in Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Rangeley Capital LLC increased its position in Oaktree Acquisition Corp. III Life Sciences by 52.8% during the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock worth $647,000 after purchasing an additional 21,156 shares in the last quarter.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.